ライフサイエンスコーパス: immunoglobulin G1

1 its humanized derivative, CAMPATH-1H (human immunoglobulin G1).

2 s fused in frame with the Fc domain of human immunoglobulin G1.

3 Gun immunizations with SERA plasmid DNA was immunoglobulin G1.

4 elia-specific antibody responses, especially immunoglobulin G1.

5 ain of MHVR fused to the Fc portion of human immunoglobulin G1.

6 iotherapeutic filgrastim, and the Fc part of immunoglobulin G1.

7 One Fab was converted to immunoglobulin G1 and analyzed for reactivity with perip

8 res priming of NK cells by immobilized human immunoglobulin G1 and costimulation through CD137L expre

9 eloped an anti-PC response consisting mainly immunoglobulin G1 and expressed the T15 heavy chain.

10 tained for all mAbs analyzed, including both immunoglobulin G1 and G2 molecules.

11 odies were found in 150 individuals (56.8%); immunoglobulin G1 and G4 were the predominant subclasses

12 ction of the Th2-associated antibody isotype immunoglobulin G1 and mediate airway inflammatory diseas

13 ured B cells, inducing moderate increases in immunoglobulin G1 and stronger increases in immunoglobul

14 LL clones were prepared as recombinant human immunoglobulin G1 and used as primary antibodies in enzy

15 increased serum levels of interleukin-4 and immunoglobulins G1 and E directed against hepatic triflu

16 Collision cross-sections (CCS) of immunoglobulins G1 and G4 have been determined using lin

17 Using beta2-microglobulin, immunoglobulin G1, and human growth hormone as model sys

18 ng and a radiotracer ((99m)Tc-labeled rhesus immunoglobulin G1 anti-CD4R1 (Fab')2), we sequentially i

19 Individuals with detectable immunoglobulin G1 anti-RAMA-pr (n = 24) had fewer positi

20 Interestingly, immunoblotting with anti-immunoglobulin G1 (anti-IgG1) and anti-IgG2 specific mon

21 nd characterization of two murine monoclonal immunoglobulin G1 antibodies (MAbs), 1-F1 and 2-B12, whi

22 g supernatants and an increase in G-specific immunoglobulin G1 antibodies.

23 ated the antitumor activity of cetuximab, an immunoglobulin G1 antibody directed at the epidermal gro

24 node and CNS and increased antigen-specific immunoglobulin G1 antibody production.

25 Immunoglobulin G1 antibody responses were also reduced i

26 Ramucirumab is a human immunoglobulin G1 antibody that binds vascular endotheli

27 y IMC-A12, is a recombinant human monoclonal immunoglobulin G1 antibody that targets insulin-like gro

28 An Fn14-specific blocking human immunoglobulin G1 antibody variant with compromised anti

29 b, termed M1, was converted to a full-length immunoglobulin G1 antibody, M1g1, and M1g1 was produced

30 sponse, as indicated by a marked increase in immunoglobulin G1 antibody.

31 inity engineered human anti-PD-L1 monoclonal immunoglobulin-G1 antibody that inhibits the interaction

32 comparison of the F105 structure to that of immunoglobulin G1 b12, a much more potent and broadly ne

33 IA (CD16) receptor expression modulate human immunoglobulin G1 binding and antibody-dependent cell-me

34 F2 protein linked to the Fc portion of human immunoglobulin G1 (BZLF2.Fc) was expressed from mammalia

35 Antibodies of the immunoglobulin G1 class are induced in mice by T-cell-de

36 he H7 HA and either influenza virus-specific immunoglobulin G1 concentration or age.

37 (GM-CSF) or tumor necrosis factor (TNF), or immunoglobulin G1 (control), starting at 1 month of age.

38 ain Fv antibody fragments fused to the human immunoglobulin G1-derived Fc fragment under the control

39 t somatic larval antigens and changing to an immunoglobulin G1-dominated response directed at tyvelos

40 b is a second-generation, recombinant, human immunoglobulin G1 EGFR antibody.

41 mab is a second-generation recombinant human immunoglobulin G1 EGFR monoclonal antibody that competit

42 s then recombinantly engineered with a human immunoglobulin G1 Fc region to construct the fully human

43 (OBZ) is a recombinant type II anti-CD20 and immunoglobulin G1 Fc-optimized monoclonal antibody (mAb)

44 trials are full-size antibodies mostly in an immunoglobulin G1 format of about 150 kDa in size.

45 kilodalton TNF receptor linked to the murine immunoglobulin G1 heavy chain.

46 The quantitative analysis of human immunoglobulin G1 (hIgG1) by mass spectrometry is common

47 rms of obinutuzumab, particularly when human immunoglobulin G1 (hIgG1) mAbs were compared.

48 A panel of immunoglobulin G1 human monoclonal antibodies (HMAbs) to

49 0) domains linked to the Fc portion of human immunoglobulin G1 (huTNFR:Fc).

50 Adalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting

51 ormans infection and the efficacy of passive immunoglobulin G1 (IgG1) administration were investigate

52 , and 28 induced peak serum anti-HIV peptide immunoglobulin G1 (IgG1) and IgA titers of 1:131,072 and

53 nd the TH2-dependent serum concentrations of immunoglobulin G1 (IgG1) and IgE in itchy mice were also

54 in the presence and absence of anti-capsular immunoglobulin G1 (IgG1) and IgE monoclonal antibody (MA

55 In cattle, both immunoglobulin G1 (IgG1) and IgG2 can fix complement, bu

56 as the production of antigen-specific serum immunoglobulin G1 (IgG1) and IgG2a antibodies.

57 t assay-based examination of murine sera for immunoglobulin G1 (IgG1) and IgG2a immunoreactivity agai

58 sponse, where equivalent titers of anti-TTFC immunoglobulin G1 (IgG1) and IgG2a in serum were accompa

59 Serum enzyme-linked immunosorbent assays for immunoglobulin G1 (IgG1) and IgG2a revealed a predominan

60 n H. pylori-specific interleukin-12 and both immunoglobulin G1 (IgG1) and IgG2a serum titers followin

61 nd also by preincubation with purified mouse immunoglobulin G1 (IgG1) and IgG2a, but not mouse IgG3,

62 s were accompanied by impaired production of immunoglobulin G1 (IgG1) and IgG2b antibodies in respons

63 there was an increase in the level of serum immunoglobulin G1 (IgG1) and IgG2b as well as a mild inc

64 (DTH) but also high titers of WI-1-specific immunoglobulin G1 (IgG1) and IgG2b, a result indicative

65 with wild-type H. hepaticus developed serum immunoglobulin G1 (IgG1) and IgG2c responses against H.

66 19F-CRM(197) alone was predominantly of the immunoglobulin G1 (IgG1) and IgM isotypes, but addition

67 Immunoglobulin G1 (IgG1) and immunoglobulin G3 (IgG3) an

68 icient mice produced extremely low levels of immunoglobulin G1 (IgG1) and showed increased production

69 All sera which mediate gamete lysis contain immunoglobulin G1 (IgG1) and/or IgG3 antibodies to gamet

70 ated cytotoxicity (ADCC) potency than native immunoglobulin G1 (IgG1) antibodies.

71 ing to the crystal structure of a homologous immunoglobulin G1 (IgG1) antibody (PDB: 1HZH ), the back

72 Immunoglobulin G1 (IgG1) antibody predominated after the

73 th PspA-IL-2 and PspA-GM-CSF stimulated high immunoglobulin G1 (IgG1) antibody responses.

74 splay library to generate IMC-41A10, a human immunoglobulin G1 (IgG1) antibody that binds with high a

75 In that study, a humanized immunoglobulin G1 (IgG1) antibody that efficiently neutr

76 nation of the three-dimensional structure of immunoglobulin G1 (IgG1) b12 allowed modeling of the b12

77 The broadly neutralizing antibody immunoglobulin G1 (IgG1) b12 binds to a conformationally

78 The human antibody immunoglobulin G1 (IgG1) b12 neutralizes a broad range o

79 However, one such human MAb, immunoglobulin G1 (IgG1) b12, is uniquely able to neutra

80 Fab 5H2 was converted to full-length immunoglobulin G1 (IgG1) by combining it with human sequ

81 Human immunoglobulin G1 (IgG1) contains 12 domains, and each h

82 tumor necrosis factor alpha receptor (TNFR)-immunoglobulin G1 (IgG1) Fc fusion (TNFR:Fc) gene to the

83 imals had similar levels of antigen-specific immunoglobulin G1 (IgG1) following challenge, vaccinated

84 the genetic marker (GM) 3/17 variants in the immunoglobulin G1 (IgG1) heavy chain constant region, vi

85 FVIII) product fused with the Fc fragment of immunoglobulin G1 (IgG1) in 165 patients with severe hem

86 aracterized by high levels of virus-specific immunoglobulin G1 (IgG1) in serum and very low levels of

87 m antibody responses were biased in favor of immunoglobulin G1 (IgG1) in these mice, as there was a s

88 ve with NS3-FL were highly restricted to the immunoglobulin G1 (IgG1) isotype and were inhibited by s

89 fect being most striking for antibody of the immunoglobulin G1 (IgG1) isotype.

90 The immunoglobulin G1 (IgG1) kappa antibodies HyHEL-5 and Hy

91 SWA immunoglobulin G1 (IgG1) levels explained the effect of

92 Also, virus-specific serum immunoglobulin G1 (IgG1) levels were greatly reduced and

93 Immunoglobulin G1 (IgG1) m14 was more potent than Fab m1

94 Opsonic activities of immunoglobulin G1 (IgG1) MAbs that produce patterns term

95 ation of the disulfide bond structures of an immunoglobulin G1 (IgG1) molecule and lysozyme and by th

96 ted by cation exchange chromatography, on an immunoglobulin G1 (IgG1) monoclonal antibody (mAb).

97 Infliximab is a genetically constructed immunoglobulin G1 (IgG1) murine-human chimeric monoclona

98 body levels in serum showed a dominant serum immunoglobulin G1 (IgG1) response in immunized C57BL/6 w

99 itial antibody response to L. mexicana is an immunoglobulin G1 (IgG1) response, and IgG1 preferential

100 th B7-1 and B7-2 had essentially no anti-VSV immunoglobulin G1 (IgG1) response, decreased IgG2a respo

101 ced stronger pathogen-specific Th2-dependent immunoglobulin G1 (IgG1) responses than did WT mice, and

102 e infection revealed a moderate elevation in immunoglobulin G1 (IgG1) responses, strongly enhanced Ig

103 neutralizer of infectious HeV, Fab m101, to immunoglobulin G1 (IgG1) significantly increased its cel

104 0(8) liters/mol in these studies) and of the immunoglobulin G1 (IgG1) subclass (i.e., the predominate

105 ody response consisting of predominantly the immunoglobulin G1 (IgG1) subclass and a high hemagglutin

106 nii-specific immunoglobulin primarily of the immunoglobulin G1 (IgG1) subclass with relatively little

107 icited by PsaA-Adj were predominantly of the immunoglobulin G1 (IgG1) subclass, while PsaA-IL-2 and P

108 Oral F1-V mice had higher prechallenge serum immunoglobulin G1 (IgG1) titers than s.c. F1-V mice.

109 Fc gamma RIIIa alter the binding affinity of immunoglobulin G1 (IgG1) to the receptor and have been a

110 n this report, the antiviral activity of 80R immunoglobulin G1 (IgG1), a human monoclonal antibody ag

111 Immunoglobulin G1 (IgG1), a subclass of human serum anti

112 ular domain fused to the Fc portion of human immunoglobulin G1 (IgG1), and growth factors stem cell f

113 n. immunization resulted in increased total, immunoglobulin G1 (IgG1), and IgG2a anti-HIV-1 antibody

114 which contain high levels of DTA-1-specific immunoglobulin G1 (IgG1), can induce anaphylaxis in naiv

115 ked augmentation of respiratory and systemic immunoglobulin G1 (IgG1), IgG2a, and IgA antibody levels

116 e borreliacidal activity was attributable to immunoglobulin G1 (IgG1), IgG2a, and IgG2b antibodies.

117 In a murine model of cryptococcal infection, immunoglobulin G1 (IgG1), IgG2a, and IgG2b switch varian

118 The immunoglobulin G1 (IgG1), IgG2a, and IgG2c antibody resp

119 , including the levels of RSV-specific serum immunoglobulin G1 (IgG1), IgG2a, IgA, and total IgG, and

120 ulations were found to induce high levels of immunoglobulin G1 (IgG1), IgG2b, and IgG2a antibodies al

121 Variable-region-identical mouse immunoglobulin G1 (IgG1), IgG2b, and IgG2a monoclonal an

122 tivating factor by basophils stimulated with immunoglobulin G1 (IgG1)-antigen immune complexes contri

123 ed from no effect to sharp reductions in the immunoglobulin G1 (IgG1)-to-IgG2a ratios.

124 al trials are chimeric, humanized, and human immunoglobulin G1 (IgG1).

125 munized with a mixture of vaccine and (CR2)2-immunoglobulin G1 (IgG1).

126 ed in a Th2-biased immune response with high immunoglobulin G1 (IgG1)/IgG2a antibody ratios and produ

127 tude of the antibody response as well as the immunoglobulin G1 (IgG1)/IgG2a ratio, and (iv) inclusion

128 ELISA) was used to investigate serum anti-CT immunoglobulin G1 (IgG1; long-lived response) and immuno

129 h ACI blood (RT1a) together with L6 (a human immunoglobulin G1 [IgG1] antibody as isotype control) or

130 recombinant urease-specific immunoglobulins (immunoglobulin G1 [IgG1] versus IgG2a) in murine sera at

131 The MAbs PfSSP2.1 (immunoglobulin G1 [IgG1]), PfSSP2.2 (IgG2a), and PfSSP2.

132 IMCEB10 (immunoglobulin G1 [IgG1], kappa) binds with high affinit

133 nd large increases in serum antigen-specific immunoglobulin G1/immunoglobulin E using ovalbumin or As

134 ted an increased level of CVB3-binding serum immunoglobulin G1 in mice inoculated with CVB3-PL2-mIL4/

135 oliferation and interleukin-4 (IL-4)-induced immunoglobulin G1 isotype switching.

136 d inhibited efficient class switching to the immunoglobulin G1 isotype.

137 Daratumumab, a human CD38 immunoglobulin G1 kappa (IgG1kappa) monoclonal antibody,

138 ibritumomab tiuxetan (IDEC-Y2B8) is a murine immunoglobulin G1 kappa monoclonal antibody that covalen

139 d with neutralizing antibody titers, anti-DV immunoglobulin G1 levels, and a multitypic 50% plaque re

140 lence of myelin oligodendrocyte glycoprotein immunoglobulin G1 (MOG-IgG) and associated clinical feat

141 envelope protein to the Fc region of a human immunoglobulin G1 molecule for use in binding assays.

142 2.6 microgram/ml) as the corresponding whole immunoglobulin G1 molecule.

143 laque formation) was observed with two human immunoglobulin G1 monoclonal antibodies (MAbs) at concen

144 cytic activities of three PPS-specific mouse immunoglobulin G1 monoclonal antibodies (MAbs), 1E2, 5F6

145 macrophages result in variable affinity for immunoglobulin G1 monoclonal antibodies and subsequently

146 By comparison of anti-mouse P. carinii immunoglobulin G1 monoclonal antibody (MAb) 4F11(G1) and

147 We examined here whether a fully human immunoglobulin G1 monoclonal antibody (MAb) specific to

148 Ipilimumab, an immunoglobulin G1 monoclonal antibody directed against t

149 t with atezolizumab, an engineered humanised immunoglobulin G1 monoclonal antibody that binds selecti

150 ell transplantation (SCT) using MEDI-507, an immunoglobulin-G1 monoclonal anti-CD2 antibody.

151 fused at its C terminus to the Fc segment of immunoglobulin G1 results in markedly enhanced survival

152 mice also had significantly higher anti-MoPn immunoglobulin G1 serum titers, confirming a Th2-type cy

153 -d-aspartate receptor antibodies were of the immunoglobulin G1 subclass and were able to activate com

154 ully human, recombinant monoclonal antibody (immunoglobulin G1 subclass) against insulin-like growth

155 duction and a reduction in parasite-specific immunoglobulin G1, suggesting an enhancement in Th1 resp

156 combinant p55 tumor necrosis factor receptor-immunoglobulin G1 (TNFR55-IgG1) fusion protein, decrease

157 hile platelets sensitized with a destructive immunoglobulin G1 version of the antibody (B2G1) are cle

158 PLP-specific immunoglobulin G1 was decreased in animals treated with

159 exploiting the stable architecture of human immunoglobulin G1 We used iterative experimental validat